Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 16/20 | 0.52 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | SRC | P12931 | 4/20 | 0.45 |
| ▸ | KDR | P35968 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL4039319 | 0.91 | EGFR (0.53) | EGFRERBB2KCNH2SRCKDR | |
| Trifluoroacetic Acid SCHEMBL4032839 | 0.91 | EGFR (0.58) | EGFRERBB2KCNH2SRCKDR | |
| SCHEMBL4034849 | 0.87 | EGFR (0.55) | EGFRERBB2KCNH2SRCKDR | |
| Trifluoroacetic Acid SCHEMBL4033517 | 0.85 | EGFR (0.70) | EGFRERBB2KCNH2SRC | |
| SCHEMBL4037394 | 0.83 | EGFR (0.57) | EGFRERBB2KCNH2SRCKDR | |
| Trifluoroacetic Acid SCHEMBL4034843 | 0.82 | EGFR (0.76) | EGFRERBB2KCNH2 | |
| SCHEMBL4034164 | 0.81 | EGFR (0.70) | EGFRERBB2SRCKDR | |
| Hydrochloric Acid SCHEMBL4032696 | 0.81 | EGFR (0.69) | EGFRERBB2KCNH2SRCKDR | |
| SCHEMBL4032872 | 0.81 | EGFR (0.55) | EGFRERBB2KCNH2SRCKDR | |
| SCHEMBL4041360 | 0.78 | EGFR (0.58) | EGFRERBB2KCNH2SRCKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1444211-B1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2009-01-21 | — | — | EP | disclosed |
| US-20070088044-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB | 2007-04-19 | — | — | US | disclosed |
| US-20050054662-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB (SE) | 2005-03-10 | — | — | US | disclosed |
| EP-1444211-A2 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | AstraZeneca AB (SE) | 2004-08-11 | — | — | EP | disclosed |
| WO-2003040109-A2 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054662-A1 | Quinazoline derivatives as antitumor agents | ERBB2, ERBB3, ABL1 | EGFR 4/4885ERBB2 1/4885KCNH2 1510/4885 |
| US-20070088044-A1 | Quinazoline derivatives as antitumor agents | ERBB2, EGFR, ERBB4 | EGFR 2/4885ERBB2 1/4885KCNH2 1844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.